Skip to content

The value of evaluating the ratio of neutrophil to lymphocyte cells (NLR) in predicting liver fibrosis in patients with chronic hepatitis B and fatty liver

The value of evaluating the ratio of neutrophil to lymphocyte cells (NLR) in predicting liver fibrosis in patients with chronic hepatitis B and fatty liver

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400085563
Enrollment
Unknown
Registered
2024-06-12
Start date
2024-06-13
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis B, Non-alcoholic fatty liver disease

Interventions

Chronic hepatitis B with Non-alcoholic fatty liver disease:None

Sponsors

The First People’s Hospital of Linping District, Hangzhou
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: The diagnostic criteria for HBV are based on the Chronic Hepatitis B Prevention and Treatment Guidelines (2022 Edition) formulated by the Hepatology Branch of the Chinese Medical Association and the Infectious Diseases Branch of the Chinese Medical Association in 2022. The diagnostic criteria for NAFLD refer to the 2010 edition of the Diagnosis and Treatment Guidelines for Non alcoholic Fatty Liver Disease (NAFLD) revised by the Fatty Liver and Alcoholic Liver Disease Group of the Hepatology Branch of the Chinese Medical Association. All CHB patients received treatment with nucleoside analogues. All patients sign informed consent forms.

Exclusion criteria

Exclusion criteria: Incomplete clinical information; Other types of liver diseases (such as hepatitis C, autoimmune liver disease, cholestatic liver disease) or human immunodeficiency virus infection; Using hepatotoxic drugs; Pregnant or lactating women; Have a history of kidney dialysis or organ transplantation.

Design outcomes

Primary

MeasureTime frame
Neutrophil count;Lymphocyte count;controlled attenuation parameter;liver stiffness measurement;

Countries

China

Contacts

Public ContactGu Jiaping

The First People’s Hospital of Linping District, Hangzhou

gjp1012931993@163.com+86 157 0006 0325

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026